West Pharmaceutical Services (WST) Stock Price, News & Analysis

Company Overview

West Pharmaceutical Services, Inc. is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle. Its offerings include stoppers and seals, custom-molded polymer parts, prefillable syringe systems and a range of delivery device technologies for self-administration. The company also offers development assistance, analytical testing, regulatory support and contract manufacturing, helping customers take complex parenteral products from design through commercial production while meeting stringent quality and compliance requirements.

West serves a global customer base that includes large pharmaceutical companies, emerging biotech firms and contract development and manufacturing organizations. The company operates manufacturing, research and development, and quality centers across multiple regions to support international supply chains and regulatory markets in North America, Europe, Asia-Pacific and Latin America. With an emphasis on innovation and quality control, West positions itself as a partner for customers seeking reliable containment and delivery solutions for advanced injectable therapies.

Key Stats

• Today's Range: $296.76 to $304.93
• 50-Day Range: $231.24 to $326.12
• 52-Week Range: $203.74 to $330.88
• Volume: 686,425 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $21.41 billion
• P/E Ratio: 40.52
• Dividend Yield: 0.29%
• Price Target: $322.89
• Consensus Rating: Moderate Buy

West Pharmaceutical Services Stock Analysis - MarketRank™

West Pharmaceutical Services scored higher than 80% of companies evaluated by MarketBeat, and ranked 135th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

West Pharmaceutical Services has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 2 strong buy ratings, 7 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for West Pharmaceutical Services is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

West Pharmaceutical Services has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.34%

Earnings Growth

Earnings for West Pharmaceutical Services are expected to grow by 10.34% in the coming year, from $8.61 to $9.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of West Pharmaceutical Services is 40.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of West Pharmaceutical Services is 40.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.66.

Price to Earnings Growth Ratio

West Pharmaceutical Services has a PEG Ratio of 2.53. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

West Pharmaceutical Services has a P/B Ratio of 7.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.45% of the float of West Pharmaceutical Services has been sold short.

Short Interest Ratio / Days to Cover

West Pharmaceutical Services has a short interest ratio ("days to cover") of 2.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in West Pharmaceutical Services has recently decreased by 8.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

West Pharmaceutical Services has a dividend yield of 0.29%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

West Pharmaceutical Services does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of West Pharmaceutical Services is 11.76%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 9.26% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.68

News Sentiment

West Pharmaceutical Services has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for West Pharmaceutical Services this week, compared to 6 articles on an average week.

Search Interest

12 people have searched for WST on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

3 people have added West Pharmaceutical Services to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, West Pharmaceutical Services insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,129,149.00 in company stock.

Percentage Held by Insiders

0.60% of the stock of West Pharmaceutical Services is held by insiders.

Percentage Held by Institutions

93.90% of the stock of West Pharmaceutical Services is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/23/2026
• Record date for 5/6 Dividend: 4/29/2026
• Ex-Dividend for 5/6 Dividend: 4/29/2026
• Dividend Payable: 5/06/2026
• Today: 5/17/2026
• 46th Annual William Blair Growth Stock Conference: 6/02/2026
• Next Earnings (Estimated): 7/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Health Care Supplies
• Current Symbol: NYSE:WST
• CIK: 105770
• Web: www.westpharma.com
• Phone: (610) 594-2900
• Fax: 800-345-9800
• Employees: 10,800
• Year Founded: 1923

Price Target and Rating

• Average Price Target for West Pharmaceutical Services: $322.89
• High Price Target: $350.00
• Low Price Target: $295.00
• Potential Upside/Downside: +6.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.48
• Trailing P/E Ratio: 40.52
• Forward P/E Ratio: 35.20
• P/E Growth: 2.53
• Net Income: $493.70 million
• Net Margins: 16.85%
• Pretax Margin: 20.82%
• Return on Equity: 19.03%
• Return on Assets: 14.06%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 2.71
• Quick Ratio: 2.04

Sales & Book Value

• Annual Sales: $3.07 billion
• Price / Sales: 6.97
• Cash Flow: $9.74 per share
• Price / Cash Flow: 31.11
• Book Value: $42.33 per share
• Price / Book: 7.16

Miscellaneous

• Outstanding Shares: 70,650,000
• Free Float: 70,224,000
• Market Cap: $21.41 billion
• Optionable: Optionable
• Beta: 1.17